STRYKER CORP
SYKNYSEHealthcare · Surgical & Medical Instruments & Apparatus · MI · SEC filings ↗ · Compare ⊕
View price & chart on Yahoo Finance ↗Financials
SEC XBRL · annual| FY25 | FY24 | FY23 | FY22 | FY21 | FY20 | |
|---|---|---|---|---|---|---|
| Revenue | $5.87B | $5.24B | $20.50B | $18.45B | $17.11B | $14.35B |
| Operating income | $4.89B | $3.69B | $3.89B | $2.84B | $2.58B | $2.22B |
| Net income | $654.0M | $788.0M | $3.17B | $2.36B | $1.99B | $1.60B |
| Total assets | $47.84B | $42.97B | $39.91B | $36.88B | $34.63B | $34.33B |
| Total liabilities | $25.42B | $22.34B | $21.32B | $20.27B | $19.75B | $21.25B |
| Equity | $22.42B | $20.63B | $18.59B | $16.62B | $14.88B | $13.08B |
| EPS (diluted) | $1.69 | $2.05 | $8.25 | $6.17 | $5.21 | $4.20 |
| Shares out. | 381.6M | 380.3M | 378.8M | 377.5M | 376.2M | 374.6M |
Reported figures from the company's SEC filings (XBRL). Blank where a line item isn't cleanly tagged — never estimated.
Key ratios
from filings · FY2025- Operating margin
- 83.3%
- Net margin
- 11.1%
- Return on equity
- 2.9%
- Return on assets
- 1.4%
- Return on capital (ROCE)
- 12.2%
- Liabilities / assets
- 53.1%
- Debt / equity
- 1.13×
- Book value / share
- $58.76
- Revenue growth (YoY)
- 11.9%
- Net income growth (YoY)
- −17.0%
Computed from the company's own SEC figures — no market price, so these are facts, not a valuation. Book value per share is reported equity ÷ shares; it is not the stock price.
Financial health
forensic scores · FY2025- Altman Z″ (distress)
- 3.96safe
- Accruals / assets
- −9.2%clean
- Piotroski F-Score
- 5/9mixed
Altman Z″is a textbook bankruptcy-distress score from book values only (>2.6 safe · 1.1–2.6 grey · <1.1 distress). Accruals = (net income − operating cash flow) ÷ assets; persistently high accruals are an earnings-quality red flag. Beneish M-Scoreis an eight-ratio screen comparing this year with last (M > −1.78 = elevated manipulation-risk screen, not proof). Piotroski F-Scorecounts how many of nine fundamental-health checks pass (shown as passed / applicable; we use operating margin and total liabilities as documented proxies where the exact input isn't XBRL-tagged). Computed from SEC filings — descriptive factors, not advice or a forecast.
Quality score
EDS ScoreOur own multi-factor score from free SEC data — profitability, growth, financial strength, earnings quality, and event/ownership catalysts. No market price and no licensed model: each axis is the share of source-backed checks it passes. Descriptive factors, not advice or a forecast.
Signs
● 5 good- Operating margin is positive
- Revenue is growing year-over-year
- Positive operating cash flow
- Clean earnings (low accruals)
- Altman Z″ in the safe zone
Derived from the company's own SEC figures (fundamentals, forensic scores, filing discipline) — descriptive factors, not advice or a forecast.
5%+ owners
SEC Schedule 13D / 13G · last 3 yrs- Vanguard Capital Management LlcPassive (13G)Apr 30, 2026
- Stryker Ronda EActivist (13D)Apr 14, 2026
- Vanguard Group IncPassive (13G)Mar 27, 2026
- Greenleaf TrustPassive (13G)Feb 11, 2026
Holders who disclosed a 5%+ stake. 13D signals intent to influence or control; 13G is a passive holding. Latest filing per holder — open it for the exact stake.
Short interest
FINRA · bi-monthly| Settlement | Shares short | Days to cover | Δ vs prior |
|---|---|---|---|
| May 15, 2026 | 5.8M | 1.8 | +30.3% |
| Apr 30, 2026 | 4.4M | 2.2 | -6.5% |
| Apr 15, 2026 | 4.7M | 2.6 | +6.9% |
| Mar 31, 2026 | 4.4M | 1.9 | +8.6% |
| Mar 13, 2026 | 4.1M | 1.9 | -4.9% |
Shares sold short as reported to FINRA. Days-to-cover = short shares ÷ average daily volume — higher means more potential squeeze pressure.
Material events
SEC Form 8-K · most recent- Director / officer changeMay 20, 2026
- Shareholder voteMay 8, 2026
- Results of operationsApr 30, 2026
- Regulation FD disclosureMar 23, 2026
- Regulation FD disclosureMar 12, 2026
- Other material eventMar 11, 2026
- Results of operationsJan 29, 2026
- Director / officer change · Regulation FD disclosureDec 4, 2025
Events the company reported on Form 8-K, labelled by the SEC item code it filed under — its own classification, not our interpretation.